2025-04-08 19:22:45
Latest Post
Godrej Properties delivers its highest ever quarterly and full year bookings
Poonawalla Fincorp Launches Shopkeeper Loan Business
Revolt Motors Expands to 200 Dealerships, Targets 400 by FY26
Sobha Ltd - Real Estate Operational Update - Q4 FY 2024-25
Lemon Tree Hotels signs a new property in DarjeelingStock Report
Morepen Laboratories Ltd posts consolidated PAT of Rs. 30.47 crore in Q1FY22
Posted On : 2021-07-27 12:53:22( TIMEZONE : IST )
MOREPEN LABORATORIES LTD. has reported financial results for the period ended June 30, 2021.
Financial Results (Q1 FY 2021-22) - QoQ Comparison
The company has reported total income of Rs.388.31 crores during the period ended June 30, 2021 as compared to Rs.290.76 crores during the period ended March 31, 2021.
The company has posted net profit / (loss) of Rs.30.47 crores for the period ended June 30, 2021 as against net profit / (loss) of Rs.26.76 crores for the period ended March 31, 2021.
The company has reported EPS of Rs.0.59 for the period ended June 30, 2021 as compared to Rs.0.59 for the period ended March 31, 2021.
| Financials | Q1 FY2021-22 | Q4 FY20-21 | % Change |
| Total Income | ₹ 388.31 crs | ₹ 290.76 crs |  33.55% |
| Net Profit | ₹ 30.47 crs | ₹ 26.76 crs | 13.86% |
| EPS | ₹ 0.59 | ₹ 0.59 | 0% |
Financial Results (Q1 FY 2021-22) - YoY Comparison
The company has reported total income of Rs.388.31 crores during the period ended June 30, 2021 as compared to Rs.258.97 crores during the period ended June 30, 2020.
The company has posted net profit / (loss) of Rs.30.47 crores for the period ended June 30, 2021 as against net profit / (loss) of Rs.19.36 crores for the period ended June 30, 2020.
The company has reported EPS of Rs.0.59 for the period ended June 30, 2021 as compared to Rs.0.43 for the period ended June 30, 2020.
| Financials | Q1 FY2021-22 | Q1 FY2020-21 | % Change |
| Total Income | ₹ 388.31 crs | ₹ 258.97 crs | 49.94% |
| Net Profit | ₹ 30.47 crs | ₹ 19.36 crs | 57.39% |
| EPS | ₹ 0.59 | ₹ 0.43 | 37.21% |
Mr. Sushil Suri, Managing Director and Chairman stated, "Our partnership with RDIF to manufacture Sputnik vaccine in India is a big milestone for the company. We have a capacity to manufacture up to 250 million dose per annum that can be ramped up to 500 million doses per annum. We remain committed to fight the battle of Covid and gear ourselves for fast vaccination of the nation. Morepen's commitment towards this project is step forward towards entry into biosimilars and other biologicals."
Shares of MOREPEN LABORATORIES LTD. was last trading in BSE at Rs. 66.7 as compared to the previous close of Rs. 65.3. The total number of shares traded during the day was 227704 in over 1772 trades.
The stock hit an intraday high of Rs. 68.2 and intraday low of 64.6. The net turnover during the day was Rs. 15270914.
